CL2007000974A1 - Anticuerpo monoclonal anti-nectina 2; composicion farmaceutica que lo comprende; y su uso para tratar o prevenir el cancer. - Google Patents

Anticuerpo monoclonal anti-nectina 2; composicion farmaceutica que lo comprende; y su uso para tratar o prevenir el cancer.

Info

Publication number
CL2007000974A1
CL2007000974A1 CL200700974A CL2007000974A CL2007000974A1 CL 2007000974 A1 CL2007000974 A1 CL 2007000974A1 CL 200700974 A CL200700974 A CL 200700974A CL 2007000974 A CL2007000974 A CL 2007000974A CL 2007000974 A1 CL2007000974 A1 CL 2007000974A1
Authority
CL
Chile
Prior art keywords
nectin
understands
treat
pharmaceutical composition
monoclonal antibody
Prior art date
Application number
CL200700974A
Other languages
English (en)
Inventor
Tsutomu Oshima
Shuji Sato
Tomofumi Kurokawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Priority to ARP070104425A priority Critical patent/AR063153A1/es
Publication of CL2007000974A1 publication Critical patent/CL2007000974A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
CL200700974A 2005-10-07 2007-04-05 Anticuerpo monoclonal anti-nectina 2; composicion farmaceutica que lo comprende; y su uso para tratar o prevenir el cancer. CL2007000974A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP070104425A AR063153A1 (es) 2006-10-06 2007-10-09 Anticuerpo monoclonal para prevenir/tratar el cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005295146 2005-10-07
PCT/JP2006/320429 WO2007043635A1 (ja) 2005-10-07 2006-10-06 癌の予防・治療剤

Publications (1)

Publication Number Publication Date
CL2007000974A1 true CL2007000974A1 (es) 2008-05-02

Family

ID=37942856

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200700974A CL2007000974A1 (es) 2005-10-07 2007-04-05 Anticuerpo monoclonal anti-nectina 2; composicion farmaceutica que lo comprende; y su uso para tratar o prevenir el cancer.

Country Status (9)

Country Link
US (1) US20090142346A1 (es)
EP (1) EP1932857A1 (es)
JP (1) JPWO2007043635A1 (es)
AR (1) AR060362A1 (es)
CA (1) CA2639119A1 (es)
CL (1) CL2007000974A1 (es)
PE (1) PE20080909A1 (es)
TW (1) TW200840825A (es)
WO (1) WO2007043635A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012205663B2 (en) * 2011-01-10 2017-02-02 Emory University Antibodies directed against influenza
CN110121560A (zh) * 2016-09-23 2019-08-13 Tfk株式会社 化合物或其盐、抗炎症剂、针对肺癌的抗癌剂、化合物或其盐的制造方法、炎症性疾病的治疗方法及肺癌的治疗方法
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
US12545727B2 (en) * 2019-01-13 2026-02-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human Nectin-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129685A1 (en) * 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
MXPA03002479A (es) * 2000-10-05 2004-05-24 Immunex Corp Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
CA2561947A1 (en) * 2004-04-09 2005-10-20 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer

Also Published As

Publication number Publication date
PE20080909A1 (es) 2008-08-28
JPWO2007043635A1 (ja) 2009-04-16
EP1932857A1 (en) 2008-06-18
US20090142346A1 (en) 2009-06-04
WO2007043635A1 (ja) 2007-04-19
AR060362A1 (es) 2008-06-11
CA2639119A1 (en) 2007-04-19
TW200840825A (en) 2008-10-16

Similar Documents

Publication Publication Date Title
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2008000197A1 (es) Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007003212A1 (es) Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2008001334A1 (es) Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007002879A1 (es) Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2007001995A1 (es) Compuestos derivados de pirrolotriazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el cancer.
CL2008000754A1 (es) Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos.
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008000094A1 (es) Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para aumentar la vasodilatacion.
CL2008000046A1 (es) Compuestos derivados de 2-(4-piperidin-3-il-fenil)-7-amido-2,7a-dihidro-1h-indazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir el cancer, enfermedades inflamatorias, lesiones por reperfusion, afeccione
CL2007002916A1 (es) Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
CL2007002856A1 (es) Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer.
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008000794A1 (es) Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
CL2007002021A1 (es) Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias.
CL2008000224A1 (es) Composicion farmaceutica que comprende un compuesto derivado glucopiranosilo; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
CL2007003033A1 (es) Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii.
CL2008000793A1 (es) Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.